Bozeman Matthew C, Schott Laura L, Desai Amarsinh M, Miranowski Mary K, Baumer Dorothy L, Lowen Cynthia C, Cao Zhun, Araujo Torres Krysmaru
University of Louisville Health, Louisville, Kentucky.
PINC AI™ Applied Sciences, Premier Inc, Charlotte, North Carolina.
J Health Econ Outcomes Res. 2022 Jul 1;9(2):1-10. doi: 10.36469/001c.36287. eCollection 2022.
High-protein enteral nutrition is advised for patients who are critically ill. Options include immunonutrition formulas of various compositions and standard high-protein formulas (StdHP). Additional research is needed on the health economic value of immunonutrition in a broad cohort of severely ill hospitalized patients. The study goal was to compare healthcare resource utilization (HCRU) and cost between immunonutrition and StdHP using real-world evidence from a large US administrative database. A retrospective cohort study was designed using the PINC AI™ Healthcare Database from 2015 to 2019. IMPACT® Peptide 1.5 (IP) was compared with Pivot® 1.5 (PC), and StdHP formulas. Inclusion criteria comprised patients age 18+ with at least 1 day's stay in the intensive care unit (ICU) and at least 3 out of 5 consecutive days of enteral nutrition. Pairwise comparisons of demographics, clinical characteristics, HCRU, and costs were conducted between groups. Multivariable regression was used to assess total hospital cost per day associated with enteral nutrition cohort. A total of 5752 patients were identified across 27 hospitals. Overall, a median 7 days of enteral nutrition was received over a 16-day hospital and 10-day ICU stay. Median total and daily hospital costs were lower for IP vs PC ($71 196 vs $80 696, <.001) and ($4208 vs $4373, =.019), with each higher than StdHP. However, after controlling for covariates such as mortality risk, surgery, and discharge disposition, average total hospital cost per day associated with IP use was 24% lower than PC, and 12% lower than StdHP (<.001). Readmissions within 30 days were less frequent for patients receiving IP compared with PC (<.02) and StdHP (<.001). Choice of high-protein enteral nutrition for patients in the ICU has implications for HCRU and daily hospital costs. Considering these correlations is important when comparing formula ingredients and per unit costs. Among the enteral nutrition products studied, IP emerged as the most cost-saving option, with lower adjusted hospital cost per day than PC or StdHP. Using a select immunonutrition formula for critically ill patients may provide overall cost savings for the healthcare system.
建议对重症患者采用高蛋白肠内营养。选择包括各种成分的免疫营养配方和标准高蛋白配方(StdHP)。对于广大重症住院患者群体,免疫营养的健康经济价值还需要更多研究。本研究的目的是利用美国一个大型管理数据库中的真实世界证据,比较免疫营养和StdHP之间的医疗资源利用(HCRU)和成本。使用2015年至2019年的PINC AI™医疗数据库设计了一项回顾性队列研究。将IMPACT®肽1.5(IP)与Pivot®1.5(PC)以及StdHP配方进行比较。纳入标准包括年龄在18岁及以上、在重症监护病房(ICU)至少住院1天且连续5天中至少有3天接受肠内营养的患者。对各亚组之间的人口统计学、临床特征、HCRU和成本进行成对比较。采用多变量回归评估与肠内营养队列相关的每日总住院费用。在27家医院共识别出5752例患者。总体而言,在为期16天的住院和10天的ICU住院期间,患者接受肠内营养的中位时间为7天。与PC相比,IP的总住院费用中位数和每日住院费用中位数更低(分别为71196美元和80696美元,P<0.001)以及(分别为4208美元和4373美元,P = 0.019),且两者均高于StdHP。然而,在控制了死亡率风险、手术和出院处置等协变量后,使用IP的每日平均总住院费用比PC低24%,比StdHP低12%(P<0.001)。与PC(P<0.02)和StdHP(P<0.001)相比,接受IP治疗的患者30天内再入院的频率更低。为ICU患者选择高蛋白肠内营养会对HCRU和每日住院费用产生影响。在比较配方成分和单位成本时,考虑这些相关性很重要。在所研究的肠内营养产品中,IP是最节省成本的选择,其调整后的每日住院成本低于PC或StdHP。为重症患者使用特定的免疫营养配方可能会为医疗系统节省总体成本。